HighTower Advisors’s Artelo Biosciences ARTL Stock Holding History

HighTower Advisors’s Portfolio ARTL Stock Details ARTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-163	Closed	-$14K	–	3161
2022 Q2	$14K	Buy	163 +67	+70%	+$6.59K	﹤0.01%	3036
2022 Q1	$12K	Buy	96 +37	+63%	+$4.25K	﹤0.01%	3200
2021 Q4	$8K	Sell	59 -208	-78%	-$41.1K	﹤0.01%	3164
2021 Q3	$57K	Buy	267 +37	+16%	+$9.4K	﹤0.01%	2921
2021 Q2	$74K	Buy	+230	New	+$78.6K	﹤0.01%	2851

Other funds holding ARTL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

HighTower Advisors's ARTL Position: Q3 2022 in Review

HighTower Advisors sold out of Artelo Biosciences (ARTL) in Q3 2022, closing a stake of 163 shares — an estimated $14K sold.

HighTower Advisors first reported a position in ARTL in Q2 2021 and held it in 5 quarters. The position peaked at $74K in Q2 2021. 9 funds tracked by Wall St. Rank hold ARTL as of Q3 2022.

HighTower Advisors reported no remaining Artelo Biosciences position as of Q3 2022 after selling out during the quarter.
HighTower Advisors sold 163 Artelo Biosciences shares in Q3 2022, an estimated $14K.
HighTower Advisors first reported a position in Artelo Biosciences in Q2 2021 and held it in 5 quarters.
HighTower Advisors's Artelo Biosciences position peaked at $74K in Q2 2021.
9 funds tracked by Wall St. Rank held Artelo Biosciences as of Q3 2022.

Based on HighTower Advisors's 13F filing for Q3 2022, filed 9 Nov 2022.